Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 77, Issue 12, 2016, Pages 1672-1680

  Loebel, Antony ^a   Silva, Robert ^a   Goldman, Robert ^a   Watabe, Kei ^a   Cucchiaro, Josephine ^a   Citrome, Leslie ^b   Kane, John M ^c,d  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE; PLACEBO; NEUROLEPTIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SUICIDAL IDEATION; TREMOR; VOMITING; DOSE RESPONSE; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA;

EID: 85007591469     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m10698     Document Type: Article

References (31)

1. Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry. 2015;172(7):617-629. doi:10.176/api.ajp.2015.14101329
2. OGorman C, Kapur S, Kolluri S, et al. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: Analyses from ziprasidone clinical studies. Hum Psychopharmacol. 2011;26(4-5):282-290. doi:10.102/hup.120
3. Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187(1-2):42-48. doi:10.1016/j.psychres.2010.1.017
4. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2):581-590. doi:10.1038/np.209.164
5. Kinon BJ, Chen L, Stauffer VL, et al. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol. 2010;30(3):286-289. doi:10.1097/JCP.0b013e3181dcb7c3
6. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163-1171. doi:10.1093/schbul/sbm134
7. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1-3):230-240. doi:10.1016/j.schres.208.02.021
8. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352-360. doi:10.408/JCP.v68n0301
9. Chang YC, Lane HY, Yang KH, et al. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol. 2006;26(6):554-559. doi:10.1097/01.jcp.024621.95905.8c
10. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063-2065. doi:10.176/api.ajp.160.1.2063
11. Hatta K, Ito H. Strategies for early nonresponse to antipsychotic drugs in the treatment of acute-phase schizophrenia. Clin Psychopharmacol Neurosci. 2014;12(1):1-7. doi:10.9758/cpn.2014.12.1.1
12. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69(suppl 1):4-17.
13. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181. doi:10.124/jpet.10.167346
14. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519-530. doi:10.107/s0213-012-2838-2
15. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebocontrolled trial. J Clin Psychiatry. 2009;70(6):829-836. doi:10.408/JCP.08m04905
16. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: A randomized, doubleblind, placebo-And olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-967. doi:10.176/api.ajp.201.1060907
17. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670-677.
18. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, doubleblind, placebo-And active-controlled trial. Schizophr Res. 2013;145(1-3):101-109. doi:10.1016/j.schres.2013.01.09
19. Loebel A, Citrome L, Correll CU, et al. Treatment of early non-response in patients with schizophrenia: Assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015;15(1):271. doi:10.186/s128-015-0629-0
20. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238. doi:10.1016/j.schres.205.04.08
21. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3(1):21. doi:10.186/1741-7015-3-21
22. Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol. 2014;28(4):387-394. doi:10.17/0269813517956
23. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6(2):76-85. doi:10.371/CSRP.6.2.5
24. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210. doi:10.1/j.1742-1241.2010.02587.x
25. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13(2):155-172.
26. Dold M, Fugger G, Aigner M, et al. Dose escalation of antipsychotic drugs in schizophrenia: A meta-Analysis of randomized controlled trials. Schizophr Res. 2015;166(1-3):187-193. doi:10.1016/j.schres.2015.04.024
27. Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl). 2013;229(2):245-252. doi:10.107/s0213-013-3103-z
28. Potkin SG, Keator DB, Kesler-West ML, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014;19(2):176-181. doi:10.1017/S1092852913059X
29. Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of shortterm, placebo-controlled studies. Eur Psychiatry. 2015;30(1):26-31. doi:10.1016/j.eurpsy.2014.08.01
30. Chapel S, Chiu YY, Hsu J, et al. Lurasidone dose response in bipolar depression: A population dose-response analysis. Clin Ther. 2016;38(1):4-15. doi:10.1016/j.clinthera.2015.1.013
31. Latuda (lurasidone hydrochloride) tablets, for oral use [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2013.